Closing the Confidence Gap: Conversations Around Infant RSV Protection

In this episode, ‘Closing the Confidence Gap: Conversations Around Infant RSV Protection,’ the expert pharmacists explore the following question:

1. From October to December of 2025, around 40% of mothers with an infant entering their first RSV season said they were unsure or would likely not get the RSV monoclonal antibody for passive immunity. What are your impressions of this data?

The panelists examined survey data revealing that approximately 40% of mothers with infants entering their first RSV season in 2025 expressed uncertainty or reluctance about administering the monoclonal antibody to their newborns. They interpreted this as a clear signal that more education is needed, emphasizing that maternal vaccination during pregnancy remains the preferred first line of defense, as it eliminates the need for an additional infant injection. The panelists stressed that many families are unfamiliar with RSV's potential severity, including the risk of long-term respiratory complications following hospitalization, and that pharmacists are ideally positioned to bridge this knowledge gap.

By proactively discussing both prevention options and the real-world consequences of RSV, pharmacists can help move hesitant families toward acceptance and protection.